

1 **Analysis of immunization time, amplitude, and adverse events of seven different vaccines against**  
2 **SARS-CoV-2 across four different countries.**

3

4 **Running Title:** Immunization of 7 vaccines vs SARS.CoV-2

5 Maria Elena Romero-Ibarguengoitia\*<sup>1,2</sup>, Arnulfo González- Cantú <sup>1,2</sup>, Chiara Pozzi<sup>1</sup>, Riccardo  
6 Levi<sup>3,4</sup>, Maximiliano Mollura<sup>5</sup>, Riccardo Sarti<sup>3</sup>, Miguel Angel Sanz-Sánchez<sup>1,2</sup>, Diego Rivera-Salinas  
7 <sup>1,2</sup>, Yodira Guadalupe Hernández-Ruíz<sup>1,2</sup>, Ana Gabriela Armendariz-Vázquez<sup>1,2</sup>, Gerardo Francisco  
8 Del Rio-Parra<sup>1,2</sup>, Irene Antonieta Barco-Flores<sup>1</sup>, Rosalinda González-Facio<sup>1</sup>, Elena Azzolini<sup>3,4</sup>,  
9 Riccardo Barbieri<sup>5</sup>, Alessandro Rodrigo de Azevedo Dias<sup>6</sup>, Milton Henriques-Guimaraes Júnior<sup>7</sup>,  
10 Alessandra Bastos-Borges<sup>7</sup>, Cecilia Acciardi<sup>8</sup>, Graciela Paez-Bo<sup>9</sup>; Mauro Martins Teixeira<sup>10</sup>, Maria  
11 Rescigno\*<sup>3, 4</sup>.

12

13 <sup>1</sup> Research Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León,  
14 México.

15 <sup>2</sup> Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro  
16 Garza García, Nuevo León, México.

17 <sup>3</sup>IRCCS Humanitas Clinical and Research Center, Rozzano, MI, Italy.

18 <sup>4</sup>Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, MI, Italy.

19 <sup>5</sup>Politecnico di Milano, Department of Electronic, Information and Bioengineering, MI, Italy.

20 <sup>6</sup>Health Department, Ternium Brazil, Rio de Janeiro, Brazil

21 <sup>7</sup>Research Department Fundação São Francisco Xavier, Minas Gerais, Brazil.

22 <sup>8</sup>Health Secretary, Unidad Hospitalaria San José, Campana, Buenos Aires, Argentina

23 <sup>9</sup>Laboratory Department, Hospital Interzonal General de Agudos San Felipe, San Nicolás de los  
24 Arroyos, Buenos Aires, Argentina

25 <sup>10</sup>Biochemistry and Immunology Department, ICB, Universidad Federal de Minas Gerais, Minas  
26 Gerais, Brazil

27

28

29 Correspondance:

30 Maria Elena Romero

31 MROMEROI@novaservicios.com.mx

32

33 Maria Rescigno

34 maria.rescigno@hunimed.eu

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61 **Abstract**

62  
63 Background: Scarce information exists in relation to the comparison of seroconversion and adverse  
64 events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate  
65 the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI.

66  
67 Methods: A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers  
68 were measured at baseline, 21-28 days after the first and second dose (when applicable) of the  
69 following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S,  
70 Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed.

71  
72 Results: We recruited 1867 subjects [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1  
73 and anti-S2 IgG antibodies over time ( $p < 0.01$ ). The highest increase after the first and second dose was  
74 observed in mRNA-1273 ( $p < 0.001$ ). There was an effect of previous SARS-CoV-2 infection; and an  
75 interaction of age with SARS-CoV-2, Gam-COVID-Vac and ChAdOx1-S ( $p < 0.01$ ). There was a  
76 negative correlation of Severe or Systemic AEFI (AEs) of naïve SARS-CoV-2 subjects with age and  
77 sex ( $p < 0.001$ ); a positive interaction between the delta of antibodies with Gam-COVID-Vac ( $p = 0.002$ ).  
78 Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b ( $p < 0.01$ ).  
79 mRNA-1273 had a higher number of AEFIs. The delta of the antibodies showed an association with  
80 AEFIs in previously infected individuals ( $p < 0.001$ ).

81  
82 Conclusions: The magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2  
83 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response is  
84 positively correlated with AEs in patients previously exposed to SARS-CoV-2.

85  
86 **Registration number:** NCT05228912  
87

88 **Keywords:** COVID-19, SARS-CoV-2, immunization, vaccines, seroconversion

89

## 90 **Introduction**

91 Covid-19 is a pneumonia-like disease caused by a coronavirus, named SARS-CoV-2. It is highly  
92 contagious, and the World Health Organization declared it in 2020 as a pandemic (1). SARS-CoV-2  
93 causes COVID-19 that has a wide range of clinical presentations, from asymptomatic disease to severe  
94 acute respiratory distress syndrome and death(2). SARS-CoV-2 utilizes its surface spike glycoprotein  
95 to enter host cells. Each unit of the spike trimer contains an S1 and S2 subunit, with the N-terminal S1  
96 subunit binding to the cellular angiotensin-converting enzyme 2 (ACE2) receptor through an internal  
97 receptor-binding domain (RBD)(3).

98

99 To prevent SARS-CoV-2 infection, 113 vaccines are being tested in human clinical trials, and 44 have  
100 reached the final step of testing(4). Based on the mechanism of action, vaccines can be clustered in  
101 four groups: 1) mRNA vaccines, for example, BNT162b2 mRNA and mRNA-1273. They use  
102 genetically engineered modified RNA to produce the spike protein that prompts an immune response  
103 safely. 2) Viral vector (adenovirus) vaccines, for example, ChAdOx1-S, Ad26.COV2, Ad5-nCoV, and  
104 Gam-COVID-Vac. They use a virus that has been genetically engineered so that it cannot cause  
105 disease but produces coronavirus proteins to safely generate an immune response. 3) Inactivated virus  
106 vaccines, for example, Coronavac, use a form of the virus that has been inactivated or weakened, so it  
107 does not cause disease but still generates an immune response. 4) Protein subunits vaccines, for  
108 example, NVX-CoV2373. It is a protein-based vaccine that uses harmless fragments of proteins or  
109 protein shells that mimic the SARS-CoV-2 to safely generate an immune response(5).

110 Currently BNT162b2 mRNA, mRNA-1273, ChAdOx1-S , Ad26.COV2 , Ad5-nCoV, Gam-COVID-  
111 Vac, Coronavac, have been administered to people across 587 countries(4). However, no studies have  
112 compared using the same assay and time frame the effectiveness of seroconversion and incidence of  
113 adverse event events in response to vaccines in different countries in the same study.

114 This study aimed to correlate the magnitude of the antibody response after the first and second dose (if  
115 applicable) between BNT162b2 mRNA, mRNA-1273, ChAdOx1-S, Ad26.COV2, Ad5-nCoV, Gam-

116 COVID-Vac, and Coronavac by measuring SARS-CoV-2 spike 1-2 IgG antibodies, using the same  
117 standardized assay, with previous clinical conditions and systemic and severe adverse events (AEs).

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145 **Materials and Methods.**

146 This was a multicentric observational study of volunteers who received an approved complete scheme  
147 of BNT162b2 mRNA, mRNA-1273, ChAdOx1-S, Ad26.COVID-2, Ad5-nCoV, Gam-COVID-Vac, or  
148 Coronavac COVID-19 vaccine during 2021 in five hospital centers (Hospital Clinica Nova, Humanitas  
149 Clinical and Research Center, Fundacion San Francisco Xavier, Ternium Health Center in Rio,  
150 Hospital Municipal San Jose, Hospital Interzonal de Agudos San Felipe) from four different countries:  
151 Mexico, Italy, Brazil and Argentina. This study followed STROBE guidelines (6). The study was  
152 approved by each local Institutional Review Board and conducted per the Code of Ethics of the World  
153 Medical Association (Declaration of Helsinki) for experiments that involve humans.

154

155 The inclusion criteria were volunteers of both genders, any age, who consented to participate, planned  
156 to conclude the immunization regimen of any vaccine, and agreed to be followed up for the duration of  
157 the study. The following vaccines were available: BNT162b2 mRNA, mRNA-1273, ChAdOx1-S,  
158 Ad26.COVID-2, Ad5-nCoV, Gam-COVID-Vac, or Coronavac. The exclusion criteria were to have  
159 received any SARS-CoV-2 vaccine prior to study entry.

160

161 Each country's Health System defined the vaccines available, the schedule, and dose assignment. On  
162 the vaccination day, the research team invited any subject who planned to receive any vaccine scheme,  
163 explained the project and asked to sign the informed consent. Inclusion-exclusion criteria were  
164 applied, and a plasma sample was collected. The baseline sample was taken before receiving the first  
165 dose of any SARS-CoV-2 vaccine (T0). The second (T1) and third samples (T2) were taken after 21  
166 days (+/- 7 days) of the first and second dose, respectively.

167

168 At each visit, participants had to answer a questionnaire. The basal questionnaire aimed at obtaining  
169 patients' medical history and previous SARS-CoV-2 infections. The questionnaires applied after the  
170 first and second dose of vaccines aimed at recognizing adverse events following immunization  
171 (AEFI)(7) and identifying a potential SARS-CoV-2 infection after receiving any vaccine dose. SARS-

172 CoV-2 infection was also monitored by the epidemiology team through PCR testing, which informed  
173 the research team of any new infection.

174

### 175 **Primary Outcome, IgG determination**

176 Our primary outcome was to correlate the magnitude of the antibody response to vaccination with  
177 previous clinical conditions and AEs . To determine the amount of specific anti-S1 and anti-S2 IgG  
178 antibodies against SARS-CoV-2 in plasma samples, the laboratory personnel used a  
179 chemiluminescence immunoassay (CLIA) developed by DiaSorin, which had a sensitivity of 97.4%  
180 (95% CI, 86.8-99.5) and a specificity of 98.5% (95% CI, 97.5-99.2). The results were reported as  
181 follows: <12.0 AU/ml was considered negative, 12.0 to 15.0 AU/ml was indeterminate, and > 15  
182 AU/ml was positive. This kit is comparable with other commercial kits and has been used elsewhere  
183 (8–11).

184 The variables we analyzed were age, sex, personal medical history (for example, the presence of type 2  
185 diabetes, hypertension, obstructive pulmonary disease, any heart condition, obesity, cancer, liver  
186 steatosis, any autoimmune disease), and confirmed SARS-CoV-2 (through nasal swab or serologic  
187 tests). The following AEs were considered of particular interest: fever (>37.5°C), adenopathy, diffuse  
188 rash, edema, facial paralysis, orthostatic hypotension, headache, arthralgia, myalgia, nausea, vomit,  
189 and diarrhea. Anti-S1 and anti-S2 IgG antibodies against SARS-CoV-2 were measured at baseline, 21-  
190 28 days post-first dose (S1), and 21-28 days post-second dose if applicable.

### 191 **Statistical Methods**

192 The researchers reviewed the quality control and the anonymization of the database. Normality  
193 assumption was evaluated with the Shapiro-Wilk test or Kolmogorov. Descriptive statistics such as  
194 mean, standard deviation, median, interquartile range, frequencies, and percentages were computed.  
195 Kruskal-Wallis test with Dunn’s multiple comparisons test was performed for IgG comparisons. We  
196 performed a mixed model where the dependent variable was the delta of the antibodies. The personal  
197 variability and time were constructed as a random effect, whereas each type of vaccine, age, history of

198 SARS-CoV-2, and the interaction of each vaccine with age were fixed effects. BNT162b mRNA was  
199 the reference vaccine group. For the analysis of AEs, the study population was divided into two  
200 separate cohorts by stratifying according to the history of SARS-CoV-2 infection (1050 Naïve SARS-  
201 CoV-2 subjects and 471 SARS-CoV-2 history subjects). Poisson generalized linear models (PGLM)  
202 were performed on both cohorts with the counts of AEs events after the second dose as the outcome  
203 variables. Included regressors were age, sex, body mass index, 1,000 AU/mL variation of IgG levels  
204 after the second dose compared to the baseline IgG levels, type of vaccine and the interactions between  
205 vaccines and IgG level variation. BNT162b mRNA was the reference vaccine group Missing  
206 completely at random values were analyzed through complete case analysis since missing antibody  
207 levels were less than 5% and we considered it incorrect to impute any AEFI. A sample size of 1870  
208 patients was calculated, according to the primary aim, by using a mixed model formula with an alpha  
209 of 0.05, power of 90%, the effect size of 0.15, and k=7. The statistical programs used were R v.4.0.3  
210 and Python v. 3.8.3. The analyses were two-tailed. A p-value less than 0.05 was statistically  
211 significant.

212

213

214

215

216

217

218

219

220

221

222

223

224

225



226

227

## 228 **Results.**

229 A total of 1867 patients were recruited from all countries: 1352 from Mexico, 42 from Italy, 260 from  
230 Brazil, and 213 from Argentina. The most frequent vaccine used was ChAdOx1-S in 666 subjects,  
231 Coronavac in 582, BNT162b2 mRNA in 289, Gam-COVID-Vac in 213, mRNA-1273 in 65,  
232 Ad26.COVID in 31, and Ad5-nCoV in 19. The mean (SD) age was 52 (16.8) years, being statistically  
233 different across vaccine groups ( $p < 0.05$ ) as some vaccines were proposed to a particular age group.  
234 Fifty-two % of subjects were men, 559 (30%) had obesity, and 501 (26.8%) had hypertension. Table 1  
235 shows the medical history of patients divided by vaccine type.

### 236 **History of SARS-CoV-2**

237 Positive history of SARS-CoV-2 infection was considered if the volunteer had a confirmatory swab or  
238 serological test. Additionally, it was considered if specific anti-S1 and anti-S2 IgG antibodies against  
239 SARS-CoV-2 in plasma samples were  $> 15$  AU/ml at baseline. We had a total of 627 positive cases  
240 before vaccination, of which 165 (24.8%) received ChAdOx1-S, 246 (42.2%) Coronavac, 107 (37.1%)  
241 BNT162b2 mRNA, 55 (25.8%) Gam-COVID-Vac, 31 (47.6%) mRNA-1273, 18 (58%) Ad26.COVID,  
242 and 5 (26%) Ad5-nCoV.

### 243 **Antibody titers**

244 All vaccines showed significant anti-S1 and anti-S2 IgG antibody changes with significant differences  
245 across vaccines and depending on SARS-CoV-2 history. In naïve patients, the highest increase  
246 [Median (IQR) AU/ml] after the first dose was observed in mRNA-1273 [175.5 (76.7)], then  
247 BNT162b mRNA [78.1(55)], and Ad5-nCoV [43.4(55.9)]. In subjects previously exposed to SARS-  
248 CoV-2, the highest increase after the first dose was observed in mRNA-1273 [5920(4705)], then  
249 BNT162b mRNA [2500(3080)], and ChAdOx1-S [1025(2489)].  
250 In naïve patients, the highest increase [Median (IQR) AU/ml] after the second dose (T2) was observed  
251 in mRNA-1273 [1875 (1190)], then BNT162b mRNA [998 (1241)], and Gam-COVID-Vac [501  
252 (55.9)], whereas in SARS-CoV-2 previously exposed subjects the highest increase after the second

253 dose was observed in mRNA-1273 [4950( 3060)], then Gam-COVID-Vac [3620 (5356)], and  
254 BNT162b mRNA [2630 (2672.5)]. Figure 1 and Figure S1 show the change in antibody levels through  
255 time, classified by vaccine type. Table 2 shows the antibody levels classified by vaccine type.  
256 The mixed model that showed a positive effect of SARS-CoV-2 previous infection (B=767.468,  
257  $p<0.001$ ), a positive interaction of age with previous SARS-CoV-2 infection (B=13.03,  $p=0.003$ ), and  
258 an interaction of Gam-COVID-Vac and ChAdOx1-S with age (B=46.5,  $p<0.001$ ; B=20.5;  $p=0.006$ ).  
259 With respect to BNT162b mRNA, mRNA-1273 showed a higher change in antibody titers, while all  
260 the other vaccines had less change ( $p<0.01$ ). We computed sex in the model, but there was no  
261 significant correlation, so we eliminated it from the final model. These results are shown in Table 3  
262 and Figure 2.

### 263 **Adverse Events Following Immunization (AEFI)**

264 At least one AEFI was observed after the first dose in 71% of respondents receiving BNT162b2  
265 mRNA, in 93% with mRNA-1273, 38% with Gam-COVID-Vac, 42% with Coronavac, 51% with  
266 ChAdOx1-S, 74% with Ad5-nCoV, and 81% with Ad26.COV2. After the second dose, 65%, 88%,  
267 23%, 33%, and 23% of the respondents experienced at least one AEFI after receiving BNT162b2  
268 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, and ChAdOx1-S, respectively. For each  
269 vaccine, the majority of the adverse events occurred during the first 24 hrs after injection, either after  
270 the first or the second dose. Patients receiving BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac,  
271 Coronavac, ChAdOx1-S, Ad5-nCoV, and Ad26.COV2 subjectively qualified the AEFI after the first  
272 dose as “very mild” or “mild” in 85%, 80%, 95%, 84%, 67%, 93%, and 57% of cases, respectively.  
273 The AEFI after the second dose were qualified as “very mild” or “mild” by 82%, 49%, 98%, 89%, and  
274 76% of patients receiving BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, and  
275 ChAdOx1-S respectively. Finally, 49% of patients receiving mRNA-1273 qualified for their adverse  
276 events after the second dose as “moderate”. Figure 3 shows the percentages of AEs per vaccine.  
277 AEs were evaluated by using PGLM. The model for naïve SARS-CoV-2 subjects showed a negative  
278 association of the count of adverse events with age (B=-0.0327,  $p<0.001$ ) and sex (B=-0.8145,  
279  $p<0.001$ ). A negative effect with respect to BNT162b mRNA was observed for Gam-COVID-Vac  
280 (B=-1.8582,  $p<0.001$ ), Coronavac (B=-0.5736,  $p=0.047$ ) and ChAdOx1-S (B=-0.7871,  $p=0.006$ ).

281 Finally, a positive interaction was found between the delta of antibodies due to vaccination and Gam-  
282 COVID-Vac ( $B=0.5604$ ,  $p=0.002$ ).

283 The model for subjects previously exposed to SARS-CoV-2 showed a negative association of the  
284 count of adverse events with age ( $B=-0.0190$ ,  $p=0.013$ ) and sex ( $B=-1.0042$ ,  $p<0.001$ ). The delta of the  
285 antibodies showed a positive association with the count of adverse events ( $B=0.1018$ ,  $p<0.001$ ). A  
286 positive effect with respect to BNT162b mRNA was observed for Gam-COVID-Vac ( $B=1.2737$ ,  
287  $p=0.038$ ), whereas a negative effect was observed for Coronavac ( $B=-1.1304$ ,  $p<0.001$ ). Negative  
288 interactions were also found between the delta of antibodies due to vaccination and the vaccines Gam-  
289 COVID-Vac ( $B=-8.5758$ ,  $p<0.001$ ) and ChAdOx1-S ( $B=-1.2386$ ,  $p=0.013$ ). See Tables 4 and 5 and  
290 Figure 4 for details.

### 291 **SARS-CoV-2 infection**

292 Subjects were followed up to 28 days after the second dose administration. Between the first and  
293 second dose, one (0.34%) patient with BNT162b2 mRNA, 0 with mRNA-1273, 1 (0.46%) with Gam-  
294 COVID-Vac, 3 (0.51%) with Coronavac, 4 (0.6%) with ChAdOx1-S, 2 (10%) with Ad5-nCoV and 1  
295 (3%) with Ad26.COV2 got the SARS-CoV-2 infection. After the second dose, 4 (1.3%) with  
296 BNT162b2 mRNA, 1 (1.5%) with mRNA-1273, 0 with Gam-COVID-Vac, 18 (3%) with Coronavac,  
297 and 11 (1.6%) with ChAdOx1-S became infected with SARS-CoV-2 ( $p<0.01$ ).

298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308

## 309 **Discussion**

310 This multicentric study compared the 21-28 day seroconversion, the AEFI after first and second doses,  
311 and the associated predictors of AEs of seven of the most common vaccines used worldwide:

312 BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV, and  
313 Ad26.COV2(4).

314 All vaccines showed immunogenicity and seroconversion after the complete vaccination scheme. The  
315 greatest change in antibody levels occurred with mRNA-1273, followed by BNT162b2 mRNA and  
316 Gam-COVID-Vac. Previous studies have shown a greater change in antibody titers for mRNA vector  
317 vaccines(12–14).

318 Our study found that the previous history of SARS-CoV-2 was related to an increase in change in  
319 antibody levels, as confirmed elsewhere (12). Also, we found higher levels in antibodies in older  
320 patients when they had previous SARS-CoV-2 infection and received Gam-COVID Vac or ChAdOx1-  
321 S. The previous study from Brazil did not find any association of antibody levels with age. We also  
322 found that except for the Gam-COVID Vac, in the other vaccines requiring two doses, the first dose  
323 was sufficient to induce maximal antibody levels in subjects with a history of SARS-CoV-2, as  
324 previously shown for the BNT162b2 mRNA vaccine(9,15–19)

325 The study of Logunov et al. that tested the efficacy of Gam-COVID Vac reported a higher increase of  
326 anti-SARS-CoV-2 IgG levels in the group of 18-30 years and no particular change in other age  
327 groups(20); however they excluded patients with previous SARS-CoV-2 infection, so these results are  
328 not comparable.

329 In the study conducted by Ramasamy et al., similar antibody titers were seen 28 days after the boost  
330 vaccination of ChAdOx1 across all groups, regardless of age or vaccine dose 21. It is possible that  
331 older patients in our group of the study had a more severe disease during SARS-CoV-2 infection and  
332 that they developed higher antibody titers, as it has been reported that patients aged higher than 60 can  
333 develop this condition (21).

334 For most patients, at least one AEFI occurred with all types of vaccines during the first 24 hrs. after  
335 injection, and most of them qualified the symptoms as “very mild” or “mild” both after the first and  
336 second dose, except for mRNA-1273 for which nearly half of the volunteers reported moderate  
337 symptoms after the second dose as reported previously(18,20,22–27).

338 Our models showed a higher risk for women and young people to experience AEs. A real-world study  
339 that reported AEFI of patients receiving BNT162b2 mRNA, mRNA-1273, or Ad26COV2 in one or  
340 two doses (28) , an independent studies conducted with Gam-COVID also confirmed this results  
341 (26,29). The study of Ramasamy et al. on ChAdOx1 showed more adverse events in the group of 18-  
342 55 years old(22). The study conducted by Scott A et al. showed that severe adverse events (grade 5)  
343 were more frequent in women with Ad5-nCoV (25).

344 On one hand, for the Naïve SARS-CoV-2 cohort, the vaccines Gam-COVID-Vac, Coronavac, and  
345 ChAdOx1-S were related to fewer AEs after the second dose than BNT162b mRNA, and to the best of  
346 our knowledge, there are no studies that compare AEs across these types of vaccines. Also, the delta of  
347 antibodies was related to AEs after the second dose in Gam-COVID-Vac. As previously published,  
348 mRNA-1273 had higher AEFIs when compared to BNT162b2 mRN(30).

349 On the other hand, for subjects previously exposed to SARS-CoV-2, those receiving Gam-COVID-  
350 Vac showed a greater number of AEs than BNT162b mRNA, while subjects receiving Coronavac  
351 showed significantly fewer events when compared to BNT162b mRNA. In general, an increase in the  
352 antibody levels was related to an increase in the number of AEFIs, but for people receiving Gam-  
353 COVID-Vac or ChAdOx1-S, greater changes in antibody levels corresponded to fewer AEs. This last  
354 result should be taken with caution due to the limited number of patients falling in the category. To the  
355 best of our knowledge, this has not been previously shown. The study conducted by Sung Hee-Lim et  
356 al. that compared the antibody response with adverse events in patients vaccinated with BNT162b  
357 mRNA or ChAdOx1-S reported no association with antibody change and adverse events; however,  
358 patients previously infected with SARS-CoV-2 were excluded (31).

359 This study shows a low rate of infection in all vaccine groups. However, the highest rate of SARS-  
360 CoV-2 infection in this follow-up period was for the one-dose vaccines Ad5-nCoV and Ad26.COV2.  
361 Also, Coronavac had a high rate of infection. It is important to consider that the patients were followed  
362 for a short period.

363 As a limitation of our study, we recognize that we had a small sample size in some vaccine groups  
364 such as Ad5-nCoV; however, to the best of our knowledge, there is no other study where this type of  
365 vaccine has been compared to other types of vaccines in a real-world setting. It will be of interest to  
366 follow the IgG titers for a longer period and to evaluate the effect of heterologous combinations of  
367 these vaccines.

368 This comparative study of vaccine types shows positive immunogenicity and seroconversion of  
369 BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV, and  
370 Ad26.COV2. The highest IgG response was for the mRNA vector vaccines and the lower for the  
371 inactivated vaccine. Women and young individuals developed more AEs. In the naïve SARS-CoV-2  
372 cohort, the vaccines Gam-COVID-Vac, Coronavac, and ChAdOx1-S were related to fewer AEs after  
373 the second dose of BNT162b mRNA. For patients who received Gam-COVID-Vac, higher antibody  
374 levels after the second dose were related to a greater number of AEs. In people previously exposed to  
375 SARS-CoV-2, those receiving Gam-COVID-Vac showed a greater number of AEs than BNT162b  
376 mRNA, while subjects receiving Coronavac showed significantly fewer events when compared to  
377 BNT162b mRNA. In general, an increase in antibody levels was related to AEs.

### 378 **Abbreviations**

379 Adverse events following immunization (AEFI)

380 Severe adverse events (AEs).

381

382 **Data Availability Statement:** Data are available upon reasonable request to the authors.

383

384 **Ethics statement:** Ethics committee/local Institutional Review Board from Hospital Clinica Nova,  
385 Humanitas Clinical and Research Center, Fundacion San Francisco Xavier, Ternium Health Center in  
386 Rio, Hospital Municipal San Jose, Hospital Interzonal de Agudos San Felipe gave ethical approval.

387 **Author Approval:** all authors all authors read an approved the final version of the manuscript.

388 **Author Contributions:**

389 Conceptualization: MERI, MR, MT, MASS, and EA. Formal analysis: MERI, MR, MT, MASS, AGC,  
390 CP, RL, S, MM, and RB. Investigation: MERI, AGC, MR, MT, MASS, CP, RL, RS, RB, MM, DRS,  
391 YGHR, AGAV, GFDRP, IABF, RGF, EZ, ARAD, MHG, ABB, CA, GPB, MT, and MR. Resources:  
392 MR, MT, and MASS Writing – original draft: MERI, AGC, CP, MM, RS, RL, RB, MASS, EA, DRS,  
393 YGHR, AGAV, GFDRP, IABF, RGF, EZ, ARAD, MHG, ABB, CA, GPB, MT, MR. Writing – review  
394 and editing: MERI, AGC, CP, MM, RS, RL, RB, MASS, EA, DRS, YGHR, AGAV, GFDRP, IABF,  
395 RGF, EZ, ARAD, MHG, ABB, CA, GPB, MT, MR. Project administration: MR, MT, MASS.  
396 Supervision: MERI, MT, MR, and MASS. Funding acquisition: MT, MR, and MASS. All authors  
397 contributed to the article and approved the submitted version.

398 **Funding:** This research was conducted using private funding from Techint Group of Companies.

399 **Conflict of Interest:** The authors have declared no competing interest.

400 **Acknowledgments:**

401 This project has been supported by the Techint Group of Companies.

402 We thank Erika Bienek (Techint Group Community Relations Director), Walter Bruno (Humanitas  
403 Communications Director), Cesar Bueno (Fundación São Francisco Xavier President), Mario Galli  
404 (Techint Group Communications Director), Pablo Sturiale (Apsot Director) for their support of the  
405 work and discussions.

406

407

408

409

410

411

412

413

## 414 References

- 415 1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020.  
416 [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
417 [briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020) [Accessed April 19, 2020]
- 418 2. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) –  
419 recent trends. *European Review for Medical and Pharmacological Sciences* (2020) **24**:2006–  
420 2011. doi: 10.26355/eurrev\_202002\_20378
- 421 3. Kumar S, Nyodu R, Maurya VK, Saxena SK. “Morphology, Genome Organization, Replication,  
422 and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).” In:  
423 Saxena SK, editor. *Coronavirus Disease 2019 (COVID-19)*. Medical Virology: From  
424 Pathogenesis to Disease Control. Singapore: Springer Singapore (2020). p. 23–31 doi:  
425 10.1007/978-981-15-4814-7\_3
- 426 4. Covid-19 Vaccine Tracker: Latest Updates - The New York Times.  
427 <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> [Accessed  
428 January 11, 2022]
- 429 5. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-  
430 2 Vaccines: Mechanism of Action, Efficacy and Safety. *IDR* (2021) **Volume 14**:3459–3476. doi:  
431 10.2147/IDR.S315727
- 432 6. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE  
433 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)  
434 statement: guidelines for reporting observational studies. *Ann Intern Med* (2007) **147**:573–577.  
435 doi: 10.7326/0003-4819-147-8-200710160-00010
- 436 7. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, Zou H, Sun C. Safety of SARS-CoV-2  
437 vaccines: a systematic review and meta-analysis of randomized controlled trials. *Infect Dis*  
438 *Poverty* (2021) **10**:94. doi: 10.1186/s40249-021-00878-5
- 439 8. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA, Pallavicini L,  
440 Chinali A, Campisi D, et al. Clinical and Analytical Performance of an Automated Serological  
441 Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. *J Clin*  
442 *Microbiol* (2020) **58**: doi: 10.1128/JCM.01224-20
- 443 9. Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, Rescigno M. One dose of  
444 SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from  
445 symptomatic COVID-19. *Journal of Clinical Investigation* (2021) **131**:e149154. doi:  
446 10.1172/JCI149154
- 447 10. Levi R, Ubaldi L, Pozzi C, Angelotti G, Sandri MT, Azzolini E, Salvatici M, Savevski V,  
448 Mantovani A, Rescigno M. The antibody response to SARS-CoV-2 infection persists over at least  
449 8 months in symptomatic patients. *Commun Med* (2021) **1**:32. doi: 10.1038/s43856-021-00032-0
- 450 11. Sandri MT, Azzolini E, Torri V, Carloni S, Pozzi C, Salvatici M, Tedeschi M, Castoldi M,  
451 Mantovani A, Rescigno M. SARS-CoV-2 serology in 4000 health care and administrative staff  
452 across seven sites in Lombardy, Italy. *Sci Rep* (2021) **11**:12312. doi: 10.1038/s41598-021-91773-  
453 4
- 454 12. Szczepanek J, Skorupa M, Goroncy A, Jarkiewicz-Tretyn J, Wypych A, Sandomierz D,  
455 Jarkiewicz-Tretyn A, Dejewska J, Ciechanowska K, Pałgan K, et al. Anti-SARS-CoV-2 IgG



- 456 against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and  
457 Ad26.COVS.S Vaccines. *Vaccines* (2022) **10**:99. doi: 10.3390/vaccines10010099
- 458 13. Lau O, Vadlamudi NK. Immunogenicity and Safety of the COVID-19 Vaccines Compared With  
459 Control in Healthy Adults: A Qualitative and Systematic Review. *Value in Health*  
460 (2021)S1098301521017344. doi: 10.1016/j.jval.2021.09.003
- 461 14. Rotshild V, Hirsh-Racah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of  
462 COVID-19 vaccines: a systematic review and network meta-analysis. *Sci Rep* (2021) **11**:22777.  
463 doi: 10.1038/s41598-021-02321-z
- 464 15. Krammer F, Srivastava K, the PARIS team, Simon V. Robust spike antibody responses and  
465 increased reactivity in seropositive individuals after a single dose of SARS-CoV-2 mRNA  
466 vaccine. [preprint]. *Allergy and Immunology* (2021). doi: 10.1101/2021.01.29.21250653
- 467 16. Krammer F, Srivastava K, Alshammery H, Amoako AA, Awawda MH, Beach KF, Bermúdez-  
468 González MC, Bielak DA, Carreño JM, Chernet RL, et al. Antibody Responses in Seropositive  
469 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* (2021) **384**:1372–  
470 1374. doi: 10.1056/NEJMc2101667
- 471 17. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM.  
472 Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers  
473 Previously Infected With SARS-CoV-2. *JAMA* (2021) **325**:1467–1469. doi:  
474 10.1001/jama.2021.3341
- 475 18. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truysers  
476 C, Fennema H, Spiessens B, et al. Safety and Efficacy of Single-Dose Ad26.COVS.S Vaccine  
477 against Covid-19. *N Engl J Med* (2021) **384**:2187–2201. doi: 10.1056/NEJMoa2101544
- 478 19. Samanovic MI, Cornelius AR, Gray-Gaillard SL, Allen JR, Karmacharya T, Wilson JP, Hyman  
479 SW, Tuen M, Korolov SB, Mulligan MJ, et al. Robust immune responses after one dose of  
480 BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. [preprint]. *Infectious*  
481 *Diseases (except HIV/AIDS)* (2021). doi: 10.1101/2021.02.07.21251311
- 482 20. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva  
483 AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an  
484 rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis  
485 of a randomised controlled phase 3 trial in Russia. *The Lancet* (2021) **397**:671–681. doi:  
486 10.1016/S0140-6736(21)00234-8
- 487 21. Cannistraci CV, Valsecchi MG, Capua I. Age-sex population adjusted analysis of disease severity  
488 in epidemics as a tool to devise public health policies for COVID-19. *Sci Rep* (2021) **11**:11787.  
489 doi: 10.1038/s41598-021-89615-4
- 490 22. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M,  
491 Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine  
492 administered in a prime-boost regimen in young and old adults (COV002): a single-blind,  
493 randomised, controlled, phase 2/3 trial. *The Lancet* (2020) **396**:1979–1993. doi: 10.1016/S0140-  
494 6736(20)32466-1
- 495 23. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G,  
496 Moreira ED, Zerbini C, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*  
497 *Engl J Med* (2020) **383**:2603–2615. doi: 10.1056/NEJMoa2034577

- 498 24. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,  
499 Roupael N, Creech CB, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*  
500 *Engl J Med* (2021) **384**:403–416. doi: 10.1056/NEJMoa2035389
- 501 25. Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, Ikram A,  
502 Lanas F, Lourdes Guerrero M, Muñoz Navarro SR, et al. Final efficacy analysis, interim safety  
503 analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine  
504 (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised,  
505 double-blinded, placebo-controlled phase 3 trial. *The Lancet* (2022) **399**:237–248. doi:  
506 10.1016/S0140-6736(21)02753-7
- 507 26. Jarynowski A, Semenov A, Kamiński M, Belik V. Mild Adverse Events of Sputnik V Vaccine in  
508 Russia: Social Media Content Analysis of Telegram via Deep Learning. *J Med Internet Res*  
509 (2021) **23**:e30529. doi: 10.2196/30529
- 510 27. Halder A, Imamura H, Condon S, Boroughs K, Nilsson SC, Anderson T, Catterson ID.  
511 Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination  
512 clinic for COVID-19. *Intern Med J* (2022) **52**:121–124. doi: 10.1111/imj.15623
- 513 28. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM.  
514 Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. *JAMA Netw*  
515 *Open* (2021) **4**:e2140364. doi: 10.1001/jamanetworkopen.2021.40364
- 516 29. Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise  
517 G, Kordi S, Akbari Z, Azordeh M, Ahangarkani F, et al. Side effects and Immunogenicity  
518 following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. *Sci*  
519 *Rep* (2021) **11**:21464. doi: 10.1038/s41598-021-00963-7
- 520 30. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of  
521 biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna  
522 Vaccines. *Eur Rev Med Pharmacol Sci* (2021) **25**:1663–1669. doi:  
523 10.26355/eurrev\_202102\_24877
- 524 31. Lim S-H, Choi S-H, Kim B, Kim J-Y, Ji Y-S, Kim S-H, Kim C-K, Kim T, Choo E-J, Moon J-E,  
525 et al. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare  
526 Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine. *Vaccines* (2021)  
527 **9**:1379. doi: 10.3390/vaccines9121379

528

529

530

531

532

533

534

535

536

537

538

539

540 **Figure 1. IgG antibody levels by vaccine.**

541 IgG antibody response was measured in serum of naïve and SARS-CoV-2 previously exposed (SARS-CoV-2  
542 Exp) subjects at different time points (T0, T1 and T2) and vaccinated with different vaccine types. Samples  $\geq 15$   
543 AU/mL were considered positive. Log scale on y axis. The box plots show the interquartile range, the horizontal  
544 lines show the median values, and the whiskers indicate the minimum-to-maximum range. Each dot corresponds  
545 to an individual subject. P- values were determined using 2-tailed Kruskal-Wallis test with Dunn's multiple  
546 comparisons test. P values refer to baseline (T0) when there are no connecting lines.

547 **Figure 2. Antibody titers classified by age type of vaccine and Time**

548 Figure shows change in antibody concentration through age, divided SARS-CoV-2 history, and  
549 vaccine type. Antibodies are expressed in logarithm and age has a Z distribution.

550 **Figure 3. Percentage of systemic or severe adverse events after second dose, stratified by vaccine**

551 Graph shows the percentage of systemic or severe adverse events grouped by frequency of appearance

552 **Figure 4. Forest plot for the GLM Poisson model coefficients stratified by SARS-CoV-2 history**

553 Women and young individuals developed more AEs. There is no effect on Body Mass Index. In the  
554 naïve SARS-CoV-2 cohort, the vaccines Gam-COVID-Vac, Coronavac and ChAdOx1-S are related to  
555 fewer AEFIs after the second dose than BNT162b mRNA. Also, for naïve SARS-CoV-2 patients who  
556 received Gam-COVID-Vac, higher antibody levels after the second dose were related to a greater  
557 number of AEs. In people previously exposed to SARS-CoV-2, those receiving Gam-COVID-Vac  
558 showed a greater number of AEs compared to BNT162b mRNA, while subjects receiving Coronavac  
559 showed significantly fewer events when compared to BNT162b mRNA.

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576 Table 1: General characteristics and medical history

577

	BNT162b2 mRNA (%)	mRNA-1273(%)	Gam-COVID-Vac (%)	Coronavac (%)	ChAdOx1-S (%)	Ad5-nCoV (%)	Ad26.COV2(%)	p-value
Total	289	65	200	582	666	19	31	
Obesity	54(18.6)	11(16.9)	44(22)	188(32.3)	248(37.2)	8(42.1)	6(19.3)	<0.001
Smoker	37(12.8)	10(15.3)	27(13.5)	60(10.3)	38(5.7)	2(10.5)	2(6.4)	0.001
Hypertension	36(12.4)	2(3)	77(38.5)	116 (19.9)	265(39.7)	3(15.7)	2(6.4)	<0.001
Dyslipidemia	27(9.3)	3(4.6)	55(27.5)	76 (13.5)	150 (22.5)	1(5.2)	1(3.2)	<0.001
Type2 Diabetes	13(4.4)	1(1.5)	32(16)	78(13.4)	164(24.6)	0	0	<0.001
Asthma	9 (3.1)	3(4.6)	6(3)	13 (2.3)	17 (2.5)	0	0	0.79
Other autoimmune disease such as thyroiditis or psoriasis	9(3.1)	0	4(2)	29 (4.9)	60 (9)	1(5.2)	1(3.2)	<0.001
Rheumatoid arthritis	7(2.4)	1(1.5)	16(8)	11(1.8)	56 (8.4)	0	1(3.2)	<0.001
Surgery in the last year	6(2)	0	6(3)	26(4.4)	45(6.7)	3 (15)	1(3.2)	0.002
Previous Cancer	5(1.7)	1(1.5)	1(0.5)	5(0.8)	29(4.3)	0	0	0.001
NAFLD	4 (1.3)	0	7(3.5)	27(4.6)	21(3.1)	2(10.5)	0	0.042
Immunosuppressive treatment	4(1.3)	0	3(1.5)	6(1)	11(1.6)	0	0	0.86
Other liver disease	3 (1)	0	10(5)	10(1.7)	10(1.5)	0	0	0.02

End stage renal disease	2 (0.7)	0	2(1)	3(0.5)	11(1.6)	0	0	0.44
Pregnancy	2(0.7)	1(1.5)	0	3(0.5)	0	1(5.2)	0	0.005
Cirrhosis	2 (0.7)	0	0	2(0.3)	4 (0.6)	0	0	0.88
Pulmonar Obstructive Chronic Disease	1(0.3)	0	3(1.5)	4(0.6)	8 (1.2)	0	0	0.68
Coronary heart disease	1(0.3)	0	15(7.5)	3(0.5)	23(3.4)	0	0	<0.001
Gout	1(0.3)	0	10(5)	19(3.2)	27 (4.05)	0	0	0.02
Active Cancer	0	0	1(0.5)	1(0.17)	10(1.5)	0	0	0.054
Atrial Fibrillation	0	0	13(6.5)	6(1)	36 ( 5.4)	0	0	0.001
Congestive heart failure	0	0	18(9)	1(0.2)	12( 1.8)	0	0	0.001
Stroke	0	0	2(1)	1(0.2)	13(1.9)	0	0	0.01
Trasplant	0	0	0	3(0.5)	5 (0.7)	0	0	0.63
Pregnancy	2	1	0	3(0.5)	0	1(5.2)	0	0.05

578 Table 1 shows the medical history and comparison between vaccine groups,  $p < 0.05$  was considered  
 579 statistically significant.

580

581

582

583

584

585

586

587

588

589

590

591

592 Table 2 Antibody differences between vaccine types

593

	SARS CoV-2 Naïve							p-value
Vaccine Median (IQR)	BNT162b2 mRNA (n=289)	mRNA-1273 (n=65)	Gam-COVID-Vac(n=213)	Coronavac ((n=582)	ChAdOx1-S (n=666)	Ad5-nCoV Cansino (n=19)	Ad26.COV2(n=31)	
Basal	3.8(0)	3.8 (26.6)	3.8 (0)	3.8(0.9)	3.8 (0)	3.8 (0)	3.8 (13.5)	p<0.005
After First Dose	78.1 (55.0)	175.5 (76.7)	22.1(44.5)	5.59 (8.0)	19.9 (39.6)	43.45 (55.9)	42.6 (57.5)	p<0.001
After Second Dose	998 (1241.0)	1875 (1190.0)	501 (1453.7)	109(97.6)	140.5 (199.5)	NA	NA	p<0.001
	SARS CoV-2 Positive							
Basal	66.9(130.8)	59.3 (67.9)	59.8 (157.3)	72.4 (119.0)	61.9 (134.8)	141.0 (175.2)	24 (66.7)	p<0.001
After First dose	2500.0(3080.0)	5920.0 (4705.0)	400.0 (3252.0)	264.5 (422.7)	1025.0 (2489.0)	182.0 (3734.6)	606.5 (23.69.0)	p<0.001
After Second Dose	2630.0 (2672.5)	4950.0 (3060)	3620 (5356)	279(337)	1020(1538)	NA	NA	p<0.001

594

595 \*Kruskal-Wallis test was performed for comparison, p<0.05 was considered statistically significant

596

597

598

599

600

601 Table 3: Mixed model of antibody changes

	Estimate	Std. Error	95% CI	t value	p-value
(Intercept)	1909.02	345.73	1271.81 – 2546.23	5.52	<0.001
Age	-19.40	6.79	-32.67 – -6.11	-2.855	0.004
SARS CoV2 previous infection	767.46	231.84	314.45 – 1220.31	3.31	0.001
mRNA-1273	1855.79	501.63	876.08 – 2836.04	3.69	<0.001
Gam-COVID-Vac	-2768.04	482.86	-3711.06 – -1824.4	-5.73	<0.001
Coronavac	-2184.03	430.93	-3025.82 – -1342.09	-5.06	<0.001
ChAdOx1-S	-1808.26	361.77	-2514.69 – -1101.2	-4.99	<0.001
Ad5-nCoV	-2710.10	1542.89	-5727.76 – 304.30	-1.75	0.079
Ad26.COV2	-791.46	1291.27	-3317.21 – 1731.09	-0.613	0.54
Age*mRNA-1273	-20.82	15.95	-52 – 10.34	-1.3	0.192
Age*Gam-COVID-Vac	46.57	9.15	28.69 – 64.44	5.09	<0.001
Age*Coronavac	16.78	9.44	-1.67 – 35.22	1.77	0.076

Age*ChAdOx1-S	20.51	7.46	5.92 – 35 .08	2.749	0.006
Age*Ad5-nCoV	44.44	35.86	-25.68 – 114.54	1.23	0.215
Age*Ad26.COV2	-4.24	32.52	-67.82 – 59.33	-0.13	0.896
Age*COVID-19 infection	13.03	4.44	4.35 – 21.71	2.93	0.003

602 Mixed model. The dependent variable is the delta of antibodies. Time and personal variability are  
603 random effects. Reference group BNT162b2 mRNA.

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623



624

625 Table 4: Number of systemic or severe adverse events following vaccination in SARS-CoV-2 Naïve  
626 subjects.

	$\beta$	<i>e</i>	95% CI	p-value
Intercept	0.73	2.08	0.95-4.57	0.066
Age	-0.03	0.96	0.95-0.97	<0.001
Sex (M)	-0.81	0.44	0.33-0.58	<0.001
Body Mass Index	0.015	1.01	0.99-1.03	0.175
Delta IgG	-0.21	0.80	0.60-1.06	0.128
mRNA-1273	0.46	1.59	0.71-3.54	0.255
Gam-COVID-Vac	-1.85	0.15	0.06-0.35	<0.001
Coronavac	-0.57	0.56	0.31-0.99	0.047
ChAdOx1-S	-0.78	0.45	0.25-0.79	0.006
Delta IgG*mRNA-1273	0.13	1.14	0.78-1.68	0.479
Delta IgG*Gam-COVID-Vac	0.56	1.75	1.22-2.49	0.002
Delta IgG*Coronavac	-1.63	0.19	0.01-2.39	0.201
Delta IgG*ChAdOx1-S	0.97	2.64	0.93-7.44	0.066

627 Poisson Generalized Linear Model regression. The reference group is BNT162b2 mRNA

628

629

630

631

632

633

634

635

636

637

638

639

640

641 Table 5. Number of systemic or severe adverse events following vaccination in SARS-CoV-2  
 642 previously exposed subjects.

	$\beta$	<i>e</i>	95% CI	p-value
Intercept	0.45	1.57	0.66-3.71	0.297
Age	-0.01	0.98	0.96-0.99	0.013
Sex (M)	-1.00	0.36	0.25-0.51	<0.001
Body Mass Index	0.004	1.00	0.97-1.03	0.776
Delta IgG	0.10	1.10	1.05-1.16	<0.001
mRNA-1273	0.23	1.26	0.48-3.31	0.628
Gam-COVID-Vac	1.27	3.57	1.07-11.89	0.038
Coronavac	-1.13	0.32	0.18-0.57	<0.001
ChAdOx1-S	-0.18	0.82	0.40-1.67	0.597
Delta IgG*mRNA-1273	-0.001	0.99	0.86-1.15	0.982
Delta IgG*Gam-COVID-Vac	-8.57	0.0001	0.00016-0.00022	<0.001
Delta IgG*Coronavac	0.19	1.22	0.52-2.84	0.644
Delta IgG*ChAdOx1-S	-1.23	0.28	0.10-0.76	0.013

643 Poisson Generalized Linear Model regression. Reference group is BNT162b2 mRNA

644

645

646

647

648

649

650

651

652

653



654



BNT162b2 mRNA



mRNA-1273

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.11.22272153>; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).





Gam-COVID-Vac

ChAdOx1-S




Ad5-nCoV

Ad26.COV2



Coronavac



—●— SARS CoV-2 negative

—●— SARS CoV-2 positive

Before Vaccination

After 1th dose

After 2nd dose

BNT162b2  
mRNA

mRNA-  
1273

Gam-COVID-  
Vac

Coronavac


ChAdOx1-S

Ad5-nCoV


Ad26.COV2


Antibodies (log[AU/ml])

Age (Z distribution)



Percentage of severe or systemic adverse reactions per vaccine, after 2nd dose





Poisson Generalized Linear Model Regression Exponentiated Coefficients